Brind.

Martin Brenner has taken on the role of CEO and CSO of iBio, Inc., where he is leading a collaboration with AstralBio focused on target discovery.

Steady: 0 in the last 7 days Updated oct 13

The latest in this situation

  1. iBio presented data at EASD and confirmed its Nasdaq listing.

How it started

5 reports, 2 independent, last reported Oct 13. The briefing below covers this first event.

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Martin Brenner has taken on the role of CEO and CSO of iBio, Inc., where he is leading a collaboration with AstralBio focused on target discovery.

Who's involved

What this event is mainly about
Martin Brenner

How it developed

Newest first. Tap a step to see who reported it.
  1. iBio presented data at EASD and confirmed its Nasdaq listing.1 source
  2. Marshall Wace participated in iBio's public offering on August 25, 2025.Sub-event
  3. Martin Brenner joins iBio as CEO/CSO and collaborates with AstralBio on target discovery.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • manilatimes.net
  • GlobeNewswireiBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody ther
  • Unknown outlet
1 more outlet ran the same wire story